Aytu Biopharma Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Aytu Biopharma Inc Unternehmen

Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.

Unternehmensinformationen

Unternehmens-codeAYTU

Name des UnternehmensAytu Biopharma Inc

IPO-datumOct 20, 2017

Gegründet am2015

CEOMr. Joshua R. (Josh) Disbrow

Anzahl der mitarbeiter99

WertpapierartOrdinary Share

GeschäftsjahresendeOct 20

Addresse7900 E. Union Avenue

StadtDENVER

BörseNASDAQ Capital Market Consolidated

LandUnited States of America

Postleitzahl80237

Telefon17204376580

Websitehttps://aytubio.com/

Unternehmens-codeAYTU

IPO-datumOct 20, 2017

Gegründet am2015

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Greg Pyszczymuka

Chief Commercial Officer

23.81K

+1.79%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

16.00K

--

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

12.80K

--

Mr. Carl C. Dockery

Independent Director

11.15K

--

Ms. Vivian H. Liu

Independent Director

9.82K

--

Mr. Abhinav (Abi) Jian

Independent Director

--

Mr. John A. Donofrio, Jr.

Independent Chairman of the Board

--

Mr. Joshua R. (Josh) Disbrow

Chief Executive Officer, Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Greg Pyszczymuka

Chief Commercial Officer

23.81K

+1.79%

Mr. Ryan J. Selhorn, CPA

Chief Financial Officer, Treasurer, Corporate Secretary

16.00K

--

Mr. Jarrett T. (Josh) Disbrow

Chief Business Officer

12.80K

--

Mr. Carl C. Dockery

Independent Director

11.15K

--

Ms. Vivian H. Liu

Independent Director

9.82K

--

Mr. Abhinav (Abi) Jian

Independent Director

--

Umsatzaufteilung

Währung: USDUpdate-Zeit: Sun, Apr 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

ADHD portfolio

13.82M

85.17%

Pediatric portfolio

2.40M

14.80%

Other

5.00K

0.03%

Nach RegionUSD

Name

Umsatz

Anteil

United States

16.22M

100.00%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

ADHD portfolio

13.82M

85.17%

Pediatric portfolio

2.40M

14.80%

Other

5.00K

0.03%

Aktionäre

Update-Zeit: Thu, May 15

Aktionärsstatistik

Art

Aktionärsstatistik

Aktionäre

Anteil

Nantahala Capital Management, LLC

17.61%

Stonepine Capital Management, LLC

7.52%

Disbrow (Joshua R.)

1.40%

Renaissance Technologies LLC

1.25%

Armistice Capital LLC

0.93%

Other

71.29%

Aktionärsstatistik

Aktionäre

Anteil

Nantahala Capital Management, LLC

17.61%

Stonepine Capital Management, LLC

7.52%

Disbrow (Joshua R.)

1.40%

Renaissance Technologies LLC

1.25%

Armistice Capital LLC

0.93%

Other

71.29%

Art

Aktionäre

Anteil

Hedge Fund

21.87%

Investment Advisor/Hedge Fund

9.14%

Individual Investor

2.81%

Investment Advisor

0.95%

Other

65.23%

Institutionelle Beteiligung

Update-Zeit: Mon, Mar 3

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

62

2.07M

33.62%

-278.42K

2024Q4

71

2.05M

33.28%

-280.21K

2024Q3

75

2.20M

40.58%

-328.29K

2024Q2

78

2.26M

43.50%

-3.54K

2024Q1

82

1.99M

41.33%

-356.06K

2023Q4

85

1.96M

40.81%

-395.45K

2023Q3

91

1.92M

40.24%

-406.76K

2023Q2

100

1.89M

40.00%

+821.00K

2023Q1

134

705.12K

28.77%

-175.85K

2022Q4

139

567.41K

290.31%

-193.60K

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Nantahala Capital Management, LLC

1.09M

17.61%

--

Dec 31, 2024

Stonepine Capital Management, LLC

407.55K

6.61%

-93.41K

-18.65%

Dec 31, 2024

Disbrow (Joshua R.)

86.59K

1.4%

+15.00K

+20.95%

Feb 28, 2025

Renaissance Technologies LLC

75.42K

1.22%

+700.00

+0.94%

Dec 31, 2024

Armistice Capital LLC

150.00K

2.43%

-86.00K

-36.44%

Dec 31, 2024

Geode Capital Management, L.L.C.

42.73K

0.69%

-2.37K

-5.25%

Dec 31, 2024

Citadel Advisors LLC

11.06K

0.18%

+11.06K

--

Dec 31, 2024

The Vanguard Group, Inc.

27.89K

0.45%

--

Dec 31, 2024

Pyszczymuka (Greg)

23.60K

0.38%

+209.00

+0.89%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

22.79K

0.37%

--

Dec 31, 2024

Verbundene ETFs

Update-Zeit: Tue, May 6

Name

Anteil

iShares Core S&P Total U.S. Stock Market ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

Anteil0%

DFA Dimensional US Sustainability Core 1 ETF

Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split

Datum

Art

Verhältnis

Jan 05, 2023

Merger

20<1

Jan 05, 2023

Merger

20<1

Jan 05, 2023

Merger

20<1

Jan 05, 2023

Merger

20<1

Dec 08, 2020

Merger

10<1

Dec 08, 2020

Merger

10<1

Datum

Art

Verhältnis

Jan 05, 2023

Merger

20<1

Jan 05, 2023

Merger

20<1

Jan 05, 2023

Merger

20<1

Jan 05, 2023

Merger

20<1

Dec 08, 2020

Merger

10<1

Dec 08, 2020

Merger

10<1

Dec 08, 2020

Merger

10<1

Dec 08, 2020

Merger

10<1

Aytu Biopharma Inc

2.220USD